Author

H. Nobori

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 3 Research Focus:host-pathogen & immune response· 3 Organism:mouse· 3

Frequent Co-Authors

A. Sato· 4 shared H. Sawa· 4 shared M. Sasaki· 4 shared S. Toba· 4 shared Y. Orba· 4 shared K. Tabata· 3 shared K. Uemura· 3 shared S. Kusakabe· 3 shared

Activity by Year

2022-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

A. Sato

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Combination therapy with oral antiviral and anti-inflammatory drugs improves the efficacy of delayed treatment in severe COVID-19

M. Sasaki, S. Iida, Y. Hirata, S. Kusakabe, K. Konishi, Y. Itakura, K. Tabata, M. Kishimoto, H. Kobayashi, T. Ariizumi, K. Intaruck, H. Nobori, S. Toba, A. Sato, K. Matsuno, , H. Sawa

This study shows that combining an oral antiviral with a corticosteroid improves treatment outcomes in delayed SARS-CoV-2 infection in hamsters compared to monotherapy.

bioRxiv · Jun 20, 2023Microbiology

2-Thiouridine is a broad-spectrum antiviral nucleoside analogue against positive-strand RNA viruses

K. Uemura, H. Nobori, A. Sato, S. Toba, S. Kusakabe, M. Sasaki, K. Tabata, K. Matsuno, N. Maeda, S. Ito, M. Tanaka, Y. Anraku, S. Kita, M. Ishii, K. Kanamitsu, , K. Maenaka

This study identifies 2-thiouridine as a broad-spectrum antiviral against SARS-CoV-2 and other positive-strand RNA viruses by inhibiting viral RNA synthesis.

bioRxiv · Dec 14, 2022Microbiology

Oral administration of S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and accelerates recovery from clinical aspects of COVID-19

M. Sasaki, K. Tabata, M. Kishimoto, Y. Itakura, H. Kobayashi, T. Ariizumi, K. Uemura, S. Toba, S. Kusakabe, Y. Maruyama, S. Iida, N. Nakajima, T. Suzuki, S. Yoshida, H. Nobori, , H. Sawa

This study shows that oral S-217622 reduces SARS-CoV-2 viral load and improves recovery in hamsters, with activity against multiple variants.

bioRxiv · Feb 14, 2022Microbiology

Discovery of S-217622, a Non-Covalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19

Y. Unoh, S. Uehara, K. Nakahara, H. Nobori, Y. Yamatsu, S. Yamamoto, Y. Maruyama, Y. Taoda, K. Kasamatsu, T. Suto, K. Kouki, A. Nakahashi, S. Kawashima, T. Sanaki, S. Toba, , Y. Tachibana

This paper describes the discovery of S-217622, an oral non-covalent SARS-CoV-2 3CL protease inhibitor showing antiviral activity and favorable pharmacokinetics in preclinical studies.

bioRxiv · Jan 26, 2022Biochemistry